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Trisomy 11 is a rare cytogenetic abnormality and is yet reported
to be one of the most frequent autosomal trisomies in acute
myeloid leukemia (AML).1 In a Cancer and Leukemia Group B
study, isolated trisomy 11 was identified in 13 cases (0.9%)
among 1496 consecutive adult patients with AML.2 The majority
of the patients with isolated trisomy 11 were older than 60 years
and 46% achieved a complete remission after induction
chemotherapy.2 However, only one patient remained in first
complete remission after undergoing allogeneic bone marrow
transplantation. In a recent Leukemia paper, Wang et al.3
identified 42 cases (0.008%) with trisomy 11 among B5000
patients with myelodysplastic syndrome (MDS) or MDS with
myeloproliferative features. Seventeen of the 42 patients
(median age, 75 years) had trisomy 11 as a sole abnormality
(n¼ 10) or together with one or two additional abnormalities.
Specific diagnoses in these 17 patients were refractory anemia
with excess of blasts (RAEB)-2 in 8 patients, RAEB-1 in 5,
refractory cytopenia with multilineage dysplasia in 1, therapy-
related MDS in 1 and chronic myelomonocytic leukemia-2 in 1;
bone marrow was not available for review in the remaining 1
patient. The authors compared their trisomy 11 MDS patients
Table 1 Cytogenetic, clinicopathological and outcome data in 19 patients with trisomy 11
Diagnosis at
the time of trisomy
11 detectiona
Karyotype Age
(years)/sex
Previous exposure to chemotherapy
or radiotherapy (interval
between exposure and
detection of trisomy 11)
Time from
detection of
trisomy 11 to
last follow-up or
death (months)
Status at last
follow-up
AML, n¼ 14
AML with maturation 47,XY,+11[15]/46,XY[5] 67/M None 19 Dead
AML with maturation 47,XY,+11[15]/46,XY[5] 75/M Radiotherapy after cystectomy for
transitional carcinoma of bladder
(6 years)
12 Dead
AML with maturation 47,XX,+11[20] 66/F None 13 Dead
AML with maturation 47,XY,+11[9]/46,XY[11] 76/M None 5 Dead
AML with maturation 47,XX,+11[20] 77/F Radiotherapy after total hysterectomy
for endometrial stromal sarcoma
(11 years)
3 Dead
AML with maturation 47,XX,+11[3]/48,XX,+11,+13[1]/
46,XX[16]
68/F None 5.5 Dead
AML with maturation 47,XY,+11[2]/
46,XY,del(20)(q11.2)[1]/
48,XY,+4,+8[1]/46,XY[26]
72/M None 16 Dead
AML with maturation 47,XX,+11[11]/46,XX[9] 69/F Therapy for breast cancer after
mastectomy: adriamycin and
cyclophosphamide (8 years)
2 Dead
AML with maturation 47,XY,+11[9]/46,XY[11] 64/M None 18 Alive
Acute myelomonocytic leukemia 47,XY,+11[8]/46,XY[12] 58/M None 14 NA
AML with maturation evolved
from PMF
47,XX,+11[15]/46,XX[5] 78/F Hydroxyurea for PMF (2 years) 2 Dead
Relapsed AML with maturation 47,XY,+11[17]/
46,XY,del(9)(q13q22)[3]
74/M Induction therapy: cytarabine,
6-thioguanine; maintenance therapy:
cytarabine, vincristine, 6-thioguanine,
daunorubicin, dexamethasone
(14 years)
0.25 Dead
Relapsed AML with maturation 47,XX,+11[4]/46,XX[26] 51/F Induction therapy: daunorubicin,
cytarabine and 6-thioguanine;
consolidation therapy: etoposide and
cytarabine for 3 courses (2 years)
11 Dead
Relapsed AML with maturation 47,XX,+11[8]/46,XX[7] 74/F Induction therapy: adriamycin and
cytarabine (14 years)
3 Dead
MDS, n¼ 5
RAEB-2 47,XY,+11,idic(Y)(q11.1)[6]/
46,XY[14]
72/M None 24 Dead
RAEB-2 47,XY,+11[20] 86/M None 13 Dead
RAEB-2 47,XY,+11[3]/47,XY,+8[2]/46,XY[25] 65/M None 16 Dead
RAEB-1 47,XY,+11[4]/47,XY,+9[2]/46,XY[24] 64/M None 6 NA
RAEB-1 47,XY,+11[2]/46,XY,der(1)t(1;11)
(p36.3;q13)[2]/46,XY[36]
68/M None 12 Dead
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; NA, not available; PMF, primary myelofibrosis; RAEB, refractory
anemia with excess of blasts.
aAccording to 2008 WHO classification.
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with historical controls and found their survival to be similar to
that of high-risk MDS patients. Accordingly, they concluded that
trisomy 11 should be considered a high-risk cytogenetic
abnormality in MDS.
In the current study, we sought to clarify the prevalence of
trisomy 11 in an unselected series of cytogenetic studies
performed at the Mayo Clinic over the last 20 years and
describe their clinical and pathological features. Between
January 1988 and December 2008, unique patient cytogenetic
studies were performed in 22 403 adults (age X18 years).
Among them, we identified 19 patients (B0.08%) with
abnormalities that included trisomy 11; WHO (World Health
Organization)-defined4 clinical diagnosis at the first sighting of
trisomy 11 was AML in 14 patients and MDS in 5 (Table 1).
Among the former, 10 cases constituted de novo AML and 4
constituted relapsed or secondary AML. Among the five MDS
patients, three had RAEB-2 and two had RAEB-1. Trisomy 11
occurred as a sole abnormality in 10 patients with AML, but in
only one patient with MDS (RAEB-2).
The median age at detection of trisomy 11 in AML was 71
years and in MDS was 67 years (range, 64–86). Median (range)
values in AML included 8.7 g/100ml (6.5–11.8) for hemoglobin,
6 109/l (1.2–123) for leukocytes and 96 109/l (12–444) for
platelets. The corresponding values in MDS were 9.2 g/100ml
(8.1–11.3), 1.8 109/l (1.1–3.2) and 129 109/l (78–199),
respectively. Approximately 50% of the AML patients were
exposed to either cytotoxic or radiation therapy before the
detection of trisomy 11 (Table 1). AML transformation was
documented in one patient with RAEB-2 after 23 months of
follow-up. In all the patients with relapsed AML and in one
patient with post-myelofibrosis AML, trisomy 11 was not
detected at the time of the initial diagnosis of AML or
myelofibrosis. As outlined in Table 1, the overall outcome after
detection of trisomy 11 was dismal although three AML patients
achieved complete remission with induction chemotherapy.
One patient with RAEB-2 was treated with 5-azacitidine for
three cycles without response. The median survival after
detection of trisomy 11 was 15 months for AML and 13 months
for MDS.
The current study confirms the rarity of trisomy 11 and its
association with high-risk myeloid malignancies, primarily
AML. Despite our large series of over 22 000 unique patient
cytogenetic studies, we identified only five patients with MDS
and none belonged to the low or intermediate-1 risk category.5
Furthermore, both our study and those of others indicate that
patients with trisomy 11 are older and a substantial proportion
has had previous exposure to chemotherapy or radiation
treatment. These observations, combined with the fact that
internal tandem duplication of the MLL and FLT3 genes
frequently accompany trisomy 11,6 makes it difficult to assign
an independent prognostic weight to trisomy 11. Therefore,
although it is reasonable to conclude that trisomy 11 clusters
with AML and higher-risk MDS, it is both scientifically
inaccurate and practically extraneous to suggest its formal
categorization as a ‘poor’ outcome karyotype in MDS.3
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